Form 4: Elicio Therapeutics Director Acquires Stock Options

Yekaterina Chudnovsky, a director of Elicio Therapeutics, acquired stock options exercisable for 7,900 shares of common stock.

Summary

• On May 19, 2025, Yekaterina Chudnovsky, a director of Elicio Therapeutics, acquired stock options.
• The options are exercisable for 7,900 shares of common stock at a price of $5.84 per share.
• The options vest fully on the earlier of May 19, 2026, or the next annual meeting of the company's stockholders after the grant date, contingent upon continued service to the issuer.
• The expiration date for the options is May 19, 2035.
• Following the transaction, Chudnovsky directly owns 7,900 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, Elicio Therapeutics, director, Form 4, beneficial ownership, ELTX, Yekaterina Chudnovsky